cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cognition Therapeutics Inc
1 own
3 watching
Current Price
$1.82
$-0.08
(-4.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
53.44M
52-Week High
52-Week High
3.49000
52-Week Low
52-Week Low
0.90000
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization53.44M
icon52-Week High3.49000
icon52-Week Low0.90000
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Cognition Therapeutics Inc do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer s disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Read More
How much money does Cognition Therapeutics Inc make?
News & Events about Cognition Therapeutics Inc.
Globe Newswire
9 months ago
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimers disease. The University of ...
Globe Newswire
1 year ago
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimers Disease, Dementia with Lewy Bodies and Geographic AtrophyNEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that a review ...
Globe Newswire
1 year ago
PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.(Nasdaq: CGTX) (the Company or Cognition) has released its fourth Conversations video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, ...
Globe Newswire
1 year ago
- CEO Participating on Panel Hosted by Alzheimers Drug Discovery Foundation -NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of ...
Globe Newswire
1 year ago
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating ...
Frequently Asked Questions
Frequently Asked Questions
What is Cognition Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cognition Therapeutics Inc shares?
plus_minus_icon
How can I buy Cognition Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cognition Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cognition Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cognition Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cognition Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cognition Therapeutics Inc?
plus_minus_icon
What percentage is Cognition Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cognition Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.82
$-0.08
(-4.21%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00